Objective: To evaluate the safety and efficacy of the Phil liquid embolic agent in non-neurological embolization procedures. M&M: Thirty-five patients with a mean age of 62.5 years underwent percutaneous embolization using Phil for the treatment of visceral arterial bleedings in 20/35 patients (including three gluteal, one bladder, two superior mesenteric, three epigastric, one deep femoral, five internal iliac, four intercostal, and one lingual arteries), splanchnic pseudoaneurysms in 11/35 patients (including three hepatic, five splenic, and three renal arteries), pancreatic bleeding metastasis in 1/35 patient, and gastric bleeding varices in 3/35 patients. Phil is composed of a non-adhesive copolymer dissolved in DMSO (Anhydrous Dimethyl Sulfoxide) with different viscosity. Procedures were performed slowly under continuous fluoroscopic guidance to avoid embolization of non-target vessels. Results: Clinical success was obtained with a single intervention in 34 cases (97.15%), while a repeated procedure was required in one case (2.85%). No technical complications nor non-target embolization occurred. A case of post-embolic syndrome was noted (2.85%) in one patient. DMSO administration-related pain was successfully controlled by medical therapy. Conclusion: Phil can be considered a safe and effective embolic agent for the treatment of non-neurologic bleeding.

Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions / Lucatelli, Pierleone; Corona, Mario; Teodoli, Leonardo; Nardis, Piergiorgio; Cannavale, Alessandro; Rocco, Bianca; Trobiani, Claudio; Cipollari, Stefano; ZILAHI DE GYURGYOKAI, Simone; Bezzi, Mario; Catalano, Carlo. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:4(2021). [10.3390/jcm10040701]

Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions

Pierleone Lucatelli;Mario Corona;Leonardo Teodoli
;
Alessandro Cannavale;Bianca Rocco;Claudio Trobiani;Stefano Cipollari;Simone Zilahi de Gyurgyokai;Mario Bezzi;Carlo Catalano
2021

Abstract

Objective: To evaluate the safety and efficacy of the Phil liquid embolic agent in non-neurological embolization procedures. M&M: Thirty-five patients with a mean age of 62.5 years underwent percutaneous embolization using Phil for the treatment of visceral arterial bleedings in 20/35 patients (including three gluteal, one bladder, two superior mesenteric, three epigastric, one deep femoral, five internal iliac, four intercostal, and one lingual arteries), splanchnic pseudoaneurysms in 11/35 patients (including three hepatic, five splenic, and three renal arteries), pancreatic bleeding metastasis in 1/35 patient, and gastric bleeding varices in 3/35 patients. Phil is composed of a non-adhesive copolymer dissolved in DMSO (Anhydrous Dimethyl Sulfoxide) with different viscosity. Procedures were performed slowly under continuous fluoroscopic guidance to avoid embolization of non-target vessels. Results: Clinical success was obtained with a single intervention in 34 cases (97.15%), while a repeated procedure was required in one case (2.85%). No technical complications nor non-target embolization occurred. A case of post-embolic syndrome was noted (2.85%) in one patient. DMSO administration-related pain was successfully controlled by medical therapy. Conclusion: Phil can be considered a safe and effective embolic agent for the treatment of non-neurologic bleeding.
2021
Keywords: bleeding; liquid embolic agent; non-neurologic intervention; transcatheter embolization.
01 Pubblicazione su rivista::01a Articolo in rivista
Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions / Lucatelli, Pierleone; Corona, Mario; Teodoli, Leonardo; Nardis, Piergiorgio; Cannavale, Alessandro; Rocco, Bianca; Trobiani, Claudio; Cipollari, Stefano; ZILAHI DE GYURGYOKAI, Simone; Bezzi, Mario; Catalano, Carlo. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:4(2021). [10.3390/jcm10040701]
File allegati a questo prodotto
File Dimensione Formato  
Phil.pdf

accesso aperto

Note: Lucatelli_Use of Phil Embolic Agent_2021
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.5 MB
Formato Adobe PDF
1.5 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1692476
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact